---
schema_version: "secwatch.filing_event.v1"
accession: "0001651308-23-000025"
form_type: "8-K"
ticker: "ONC"
cik: "0001651308"
company_name: "BeOne Medicines Ltd."
filed_at: "2023-01-31T23:59:59+00:00"
generated_at: "2026-06-20T05:28:19.052516+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Amgen relinquishes board appointment right at BeiGene; Hooper remains

## Summary
- Amgen gave up its right to designate a director to BeiGene's board under an amendment to the 2019 Share Purchase Agreement.
- Anthony C. Hooper, Amgen's former designee, will continue serving as director on BeiGene's board until his term ends in 2025.
- The amendment was effective January 30, 2023; Amgen cited BeiGene's global growth as the reason for relinquishing the right.
- Amgen invested approximately $2.78 billion in BeiGene in 2019, receiving shares and board appointment rights.

## SEC filing metadata
- accession: 0001651308-23-000025
- form_type: 8-K
- ticker: ONC
- cik: 0001651308
- company_name: BeOne Medicines Ltd.
- filed_at: 2023-01-31T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1651308/000165130823000025/0001651308-23-000025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1651308/000165130823000025/bgne-20230130.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001651308-23-000025
- JSON: https://secwatch.observer/filing/0001651308-23-000025.json
- Plain text: https://secwatch.observer/filing/0001651308-23-000025.txt

## Key facts
- Material Agreements
  BeOne Medicines Ltd. amended Amendment No. 3 to the Share Purchase Agreement with Amgen Inc. (effective 2023-01-30).
  - Action: amendment
  - Agreement: equity purchase
  - Counterparty: Amgen Inc.
  - Effective: 2023-01-30
  source text: On January 30, 2023, on account of the Company’s global growth, Amgen elected to relinquish its right to appoint a designated director to the Company’s board of directors, pursuant to an Amendment No. 3 to the Share Purchase Agreement (the “Amendment”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1651308/000165130823000025/0001651308-23-000025-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.